| Trial ID: | L0396 |
| Source ID: | NCT06236672
|
| Associated Drug: |
Glp-1 Receptor Agonist
|
| Title: |
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Chronic Kidney Diseases
|
| Interventions: |
DRUG: GLP-1 receptor agonist|DRUG: basal insulin
|
| Outcome Measures: |
Primary: change in HbA1c (%), To compare change in HbA1c from baseline to follow-up between the GLP-1 RA initiation group and the basal insulin initiation group, baseline to 26-to-52 weeks follow-up |
|
| Sponsor/Collaborators: |
Sponsor: LMC Diabetes & Endocrinology Ltd. | Collaborators: Novo Nordisk Canada Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
348
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2023-02-15
|
| Completion Date: |
2023-11-29
|
| Results First Posted: |
|
| Last Update Posted: |
2024-02-01
|
| Locations: |
LMC Diabetes & Endocrinology Ltd., Toronto, Ontario, M4G 3E8, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT06236672
|
